Advertisement

Topics

Search Results for "Breast Pap Test Trial"

23:55 EDT 30th May 2016 | BioPortfolio

Matching Channels

Sniff test

Schilling test

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...

Breast Lumps

OncoDEEP

At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer t...

Matching News

Medical News Today: Multi-gene test identifies early breast cancer that may be spared chemo

A multi-gene test that identifies early breast cancer patients who can be treated with anti-hormonal therapy alone and no chemotherapy has shown successful results in a trial.

Keytruda, talazoparib join I-SPY 2

QuantumLeap Healthcare Collaborative said it is adding two new treatment arms to the ongoing, adaptive Phase II I-SPY 2 trial, which is testing therapies to treat patients with hormone receptor (HR)-n...

'Ecologically diverse' breast cancers more likely to be deadly

(Institute of Cancer Research) Breast cancers which are particularly complex and diverse, as judged by a test used in ecology to analyze species of animals and plants, are particularly likely to progr...

Gene Test May Spare Some Breast Cancer Patients From Chemo

FRIDAY, March 11, 2016 -- A new genetic test seems to accurately identify women with early stage breast cancer who don't need chemotherapy, German researchers report. The test is called the 21-gene re...

Medical News Today: Novel test detects potentially harmful chemicals in breast milk

Researchers have created a test that they say can accurately detect the presence of bisphenol A and parabens - known endocrine-disrupting chemicals - in breast milk.

Spectrum Pharmaceuticals begins enrolling in SPI-2012 breast cancer trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, has initiated the planned registratio...

Full dose radiotherapy to whole breast may not be needed in early breast cancer

(ECCO-the European CanCer Organisation) Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with ...

Shuwen to Market Diagnostic in China for Germany's BioNTech

Shuwen Biotech, a Hangzhou-area IVD company, formed a strategic partnership with Germany's BioNTech Diagnostics that gives Shuwen exclusive rights to commercialize BioNTech’s molecular breast ca...

Matching PubMed Articles

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.

In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compare...

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.

IMPORT HIGH is a multi-centre randomised UK trial testing dose escalated intensity modulated radiotherapy after tumour excision in women with early breast cancer and higher than average local recurren...

Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

Serum levels of 25-OH vitamin D3 (vitamin D) have been shown to be prognostic for disease-free survival in patients with breast cancer. We investigated the predictive value of these levels for patholo...

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients with HER2-positive breast cancer. Trastuzumab, an anti-HER2 monoclonal antibody, has pre...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement